Phase 1 first-in-human study of the enhancer of zeste-homolog 2 (EZH2) histone methyl transferase inhibitor E7438
| Date | 03 March 2015 |
| Event | 13th International Congress on Targeted Anticancer Therapies |
| Session | Epigenetics and chaperones |
| Topics | Anti-Cancer Agents & Biologic Therapy Drug Development |
| Presenter | Vincent Ribrag |